Aug. 26 at 3:10 AM
$ABCL An 83% reduction in hot flashes versus 33% for placebo is the kind of data that rewrites a market, and Truist's
$30 target is only the first move. Two weeks ago this was a fee-for-service shop; apparently the story changes as fast as the share price does.
Key takeaways:
The
$200‑million secondary offering in mid‑August was oversubscribed (including pre‑funded warrants). Instead of taking the opportunity to exit positions after data release, institutions added to their holdings. The largest institutional shareholder is biotech‑focused Baker Bros., with a position valued at approximately
$259 million.
